7th ICHNO Abstract book

7th ICHNO 7 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 14 – 16 March 2019 Barcelona, Spain __________________________________________________________________________________________ page 83

Conclusion The experience gained by foreign and domestic oncology science claims that the whole complex of anti-cancer control measures is the result of timely and proper registration of malignant tumors. Scientifically based planning aimed at preventing, early detection of tumors, providing medical care and rehabilitation of cancer patients are impossible without timely receipt and analysis of reliable information about the morbidity and mortality of the population of the malignant tumors. PO-156 Risk of appearance of second and successive neoplasms in patients with a head and neck index tumor A. Sumarroca 1 , X. León 2 , J. García 2 , M. López 2 , J.M. Costa 1 , M. Quer 2 1 Hospital Sant Joan Despí Moisès Broggi, Otorhinolaryngology, Barcelona, Spain ; 2 Hospital de la Santa Creu i Sant Pau, Otorhinolaryngology, Barcelona, Spain Purpose or Objective To analyze the incidence of appearance of second neoplasms and successive neoplasms in a cohort of head and neck squamous carcinoma patients. Material and Methods We conducted a retrospective study in 4,458 patients with an index tumor located in the head and neck diagnosed during the 1985-2016 period. We evaluated the incidence of appearance of second neoplasms and successive neoplasms along a 30 years period. Results During the follow-up, 1,203 patients (27.0%) had a second neoplasm, 242 patients (5.4%) a third neoplasm, 58 patients (1.3%) a fourth neoplasm, and 8 patients (0,2%) five or more successive neoplasms. The incidence of appearance of second neoplasms was 3.5% per year, remaining relatively constant throughout the follow-up period. Those patients with a second neoplasm had a higher risk of appearance of a third neoplasm, and those with a third neoplasm had a higher risk of a fourth one. Seventy eight percent of the second neoplasms, 88.0% of the third neoplasms and 89.6% of the fourth neoplasms appeared in locations epidemiologically related to tobacco and alcohol use. Conclusion Second neoplasms after a head and neck index tumor appear at a constant rate of 3.5% per year throughout all the follow-up period. PO-157 The Incidence and Prevalence of Head and Neck cancer in seven developed nations from 2018 to 2028 A. Sharma 1 1 Decision Resources Group Insights and Analytics Inc., Epidemiology, Bengaluru, India Purpose or Objective To estimate the incidence and prevalence of Squamous Cell Carcinoma of Head and Neck (SCCHN) in the United States, France, Germany, Spain, Italy, United Kingdom and Japan over the next ten years using a multi-factorial forecast model. Material and Methods SCCHN is a diffused clinical entity comprising multiple tumor sites in the head and neck region. We classify these sites by anatomical location, these are:

• • • •

Oral cavity Oropharynx Hypopharynx

Other SCCHN (pharynx unspecified, waldeyer ring, overlapping lesion of lip, oral cavity and pharynx, nasal cavity, middle ear and accessory sinuses). Using a critically appraised set of country-specific cancer registries, SCCHN incidence was estimated for the baseline year, which was the latest year of available data in each registry. These baseline estimates were trended over the next ten years using a risk-factor based forecast model. Smoking is an established risk factor for SCCHN; we incorporated effect of smoking on the risk of SCCHN for all tumor sites except oropharynx. Based on the published literature, oropharynx squamous cell carcinoma incidence is increasing historically, unlike other tumor sites, and this increase is mainly attributable to oral Human Papilloma Virus (HPV) infection. Thus, we incorporated effect of oral HPV infection to trend the risk of oropharynx squamous cell carcinoma. Prevalence was estimated as a cumulative incidence over preceding twenty years with adjustments for disease- specific and competing-cause mortality for each year. The incident population for all tumor sites except other SCCHN was stratified by HPV status. The incident Nasopharynx population was also stratified by Epstein-Barr virus (EBV status) in all countries except Japan. Results : The incidence of SCCHN is 17 cases per 100,000/year, resulting in 135,000 new cases in 2018. This will increase to 19 cases per 100,000/year in 2028, resulting in 148,000 new cases. The prevalence of SCCHN is 155 cases per 100,000 and 1.2 million people are living with SCCHN in 2018. This will increase to 178 cases per 100,000 and 1.4 million people living with SCCHN in 2028. Nearly 30% of SCCHN incident cases are HPV positive. Nearly 65% of nasopharynx squamous cell carcinoma incident cases are EBV positive.

• •

Larynx

Nasopharynx